Craft

AbCellera Biologics

Stock Price

$2.8

2024-10-29

Market Capitalization

$833.9 M

2024-10-29

Revenue

$75.1 M

FY, 2025

AbCellera Biologics Summary

Company Summary

Overview
AbCellera Biologics is a company that provides an AI-powered drug discovery platform for antibody therapies. It searches, decodes, and analyzes natural immune systems to find antibodies its partners can develop into drugs to prevent and treat disease. The company also provides proprietary antibody visualization software Celium.
Type
Public
Status
Active
Founded
2012
HQ
Vancouver, CA | view all locations
Website
https://abcellera.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Carl Hansen

    Carl Hansen, Chairman, CEO & President

  • Véronique Lecault

    Véronique Lecault, Director & COO

  • Andrew Booth

    Andrew Booth, Chief Financial Officer

  • Tryn Stimart

    Tryn Stimart, CLO, CCO & Corporate Secretary

    Operating MetricsView all

    Discovery Projects

    94

    Q3, 2020

    Partners

    26

    Q3, 2020

    LocationsView all

    1 location detected

    • Vancouver, British Columbia HQ

      Canada

      2215 Yukon St

    AbCellera Biologics Financials

    Summary Financials

    Revenue (FY, 2025)
    $75.1M
    Net income (FY, 2025)
    ($146.4M)
    Cash (FY, 2025)
    $C61.8M
    EBIT (FY, 2025)
    ($217.1M)
    Enterprise value
    $909.5M

    Footer menu